While Drug Approval / UK Patient access to recent Biological Dupilumab (recently approved for Asthma in USA) is still some way off for those on this side of the pond, the findings linked too below are somewhat heartening.
Providing safety data turns out acceptable, Dupilumab sounds promising for both conditions. It might well be available in the UK as early as next year - NICE are checking it out this year. Licensing by Europe / MHRA hasn’t yet (I think) occurred.
Usual reservation will apply to those Patients that it seems a good match for, i.e. User Data will be very thin as not that many folk will have been on it for any reasonable amount of time. Still, a glimmer of optimism at least.